PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 28, 2025Deleted Journal15 citationsOpen Access

Continuous pharmaceutical manufacturing and its contemporary regulatory insights

View Full Paper
AAAtlaw Abate AlemieESEbrahim Abdela SirajAYAshagrachew Tewabe Yayehrad

Key Points

  • Continuous manufacturing improves production efficiency by 90%, while also enhancing product quality by 40%.
  • Over 15 pharmaceutical products are now produced using continuous manufacturing, achieving U.S. FDA approval under ICH Q13.
  • The review identifies challenges such as regulatory hurdles and the need for stakeholder partnerships for wider implementation.
  • Harmonized efforts across disciplines are essential to develop strategies for overcoming regulatory barriers in manufacturing.

Abstract

Nowadays, continuous manufacturing is a widely accepted production system in the pharmaceutical industry, as it provides several advantages over the conventional approach. The production system offers a more efficient, consistent, and uninterrupted process integrated with a real-time production system. This improvement results in high-quality products, increased uniformity, and minimized variation during production. Specifically, continuous manufacturing reduces production time by nearly 90%, improves product quality by 40%, and enhances production efficiency by 90%. Moreover, it minimizes energy and water consumption by 25–50% and requires 30–50% less working space. Consequently, it reduces manufacturing costs and supports an environmentally friendly and sustainable production practice. The transition from conventional to continuous production processes further enhances broader manufacturing capabilities and minimizes essential stockouts by improving the market supply chain during pandemics and public health emergencies. Currently, over 15 pharmaceutical products are manufactured through a continuous process and have obtained approval from the U.S. FDA, supported by regulatory frameworks including ICH Q13, which enhances universally harmonized practice. Nevertheless, the adoption of continuous manufacturing still faces numerous challenges, including regulatory approval hurdles, integration with conventional systems, requirements for consistent compliance, advanced production techniques, and the need for various stakeholder partnerships. Hence, the main objective of this review is to navigate the existing knowledge, opportunities, challenges, and regulatory approval barriers, and to highlight potential gaps related to the continuous manufacturing process. This comprehensive review of literature was conducted through searches in standard databases such as PubMed, Google Scholar, ScienceDirect, Medline, and Elsevier. The results indicate the need for harmonized and integrated efforts across multiple disciplines to design efficient strategies for overcoming regulatory hurdles and enabling wider implementation of the continuous manufacturing process.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Alemie et al. (2025) studied this question.

synapsesocial.com/papers/68d9052941e1c178a14f58c7https://doi.org/10.1007/s42452-025-07712-9
Ask AI
Helpful
Bookmark
Share
View Full Paper